Date: 2016-10-06
Type of information: Clinical research agreement
Compound: ARC-520 and SB 9200
Company: Arrowhead Research Corporation (USA - CA) Spring Bank Pharmaceuticals (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: clinical research
Action mechanism: immunomodulator agent/RNAi. SB 9200 is Spring Bank's novel small molecule, orally-available selective immunomodulator compound being developed as both monotherapy and combination therapy as a backbone for the treatment of chronic HBV and other viral diseases.
Arrowhead's ARC-520 is being investigated for its potential to produce functional cures in patients with chronic hepatitis B virus (HBV) infection. ARC-520 intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogs act, and is designed to silence the production of all HBV gene products. The small interfering RNAs (siRNAs) in ARC-520 engage the body's normal cellular RNAi machinery and direct specific cleavage of HBV RNA transcripts, thereby reducing the levels of HBV proteins and the RNA template used to produce viral DNA.
Disease: chronic hepatitis B
Details: * On October 6, 2016, Arrowhead Pharmaceuticals and Spring Bank Pharmaceuticals announced an agreement to perform collaborative studies on Arrowhead's ARC-520 and Spring Bank's SB 9200, for the treatment of chronic Hepatitis B. The companies plan to first conduct preclinical models with both agents together and then study the agents clinically in a cohort to be added to Arrowhead's ongoing MONARCH Phase 2b study, in which patients will receive a dosing regimen that includes ARC-520, SB 9200, and an oral direct-acting antiviral.
Financial terms:
Latest news:
